Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies

The pathological hallmark of many neurodegenerative diseases is the accumulation of characteristic proteinaceous aggregates. Parkinson's disease and dementia with Lewy bodies can be characterized as synucleinopathies due to the abnormal accumulation of the protein alpha-synuclein (alpha-Syn). Studies have shown amyloidogenic proteins such as alpha-Syn and tau can exist as polymorphic aggregates, a theory widely studied mostly in their fibrillar morphology. It is now well understood that an intermediate state of aggregates, oligomers, are the most toxic species. We have shown alpha-Syn, when modified by different physiological inducers, result in distinct oligomeric conformations of alpha-Syn. Polymorphic alpha-Syn oligomers exhibit distinct properties such as aggregate size, conformation, and differentially interact with tau. In this study, we confirm alpha-Syn oligomeric polymorphs furthermore using in-house novel alpha-Syn toxic conformation monoclonal antibodies (SynTCs). It is unclear the biological relevance of alpha-Syn oligomeric polymorphisms. Utilizing a combination of biochemical, biophysical, and cell-based assays, we characterize alpha-Syn oligomeric polymorphs. We found alpha-Syn oligomeric polymorphs exhibit distinct immunoreactivity and SynTCs exhibit differential selectivity and binding affinity for alpha-Syn species. Isothermal titration calorimetry experiments suggest distinct alpha-Syn:SynTC binding enthalpies in a species-specific manner. Additionally, we found SynTCs differentially reduce alpha-Syn oligomeric polymorph-mediated neurotoxicity and propagation in primary cortical neurons in a polymorph-specific manner. These studies demonstrate the biological significance of polymorphic alpha-Syn oligomers along with the importance of polymorph-specific antibodies that target toxic alpha-Syn aggregates. Monoclonal antibodies that can target the conformational heterogeneity of alpha-Syn oligomeric species and reduce their mediated toxicity have promising immunotherapeutic potential.

Automated summary

The accumulation of proteinaceous aggregates is a pathological hallmark of many neurodegenerative diseases. Parkinson's disease and dementia with Lewy bodies are characterized by the abnormal accumulation of alpha-synuclein (alpha-Syn). Alpha-Syn and tau, amyloidogenic proteins, can exist as polymorphic aggregates. Alpha-Syn oligomeric polymorphs show distinct properties and interact differently with tau. Monoclonal antibodies targeting the conformational heterogeneity of alpha-Syn oligomeric species have potential therapeutic applications.